The field of drug discovery has long been challenged by the concept of "undruggable" targets—proteins and pathways that are crucial in disease processes but difficult to target with traditional small molecule drugs. One particularly challenging target is β-catenin, a key player in the Wnt/β-catenin
Insilico Medicine, a clinical-stage company leveraging generative artificial intelligence (AI) for drug discovery and development, has announced promising results for its novel drug, ISM5411, aimed at treating Inflammatory Bowel Disease (IBD). This gut-restricted and PHD-specific inhibitor was
The landscape of clinical trials is on the brink of a significant transformation, driven by the integration of Real World Data (RWD). By 2025, the use of RWD is expected to revolutionize the way clinical trials are conducted, offering new opportunities for efficiency, accuracy, and patient-centric
In a transformative study examining the impact of GLP-1 receptor agonist drugs on post-surgical outcomes for diabetic patients, researchers have discovered significant reductions in post-surgical complications when these medications are part of the regimen. Drugs like tirzepatide and semaglutide,
Researchers at the National University of Singapore (NUS) have developed an innovative method to enhance the effectiveness of chemotherapy while mitigating its adverse side effects. This novel approach employs brief, localized pulses of magnetic fields, which significantly increase the uptake of
Artificial Intelligence (AI) is making significant strides in various fields, and drug development is no exception. While AI's applications in text generation, facial recognition, and autonomous driving are well-known, its potential in drug discovery is equally transformative, promising to save
